icometrix (now a GE HealthCare company)

Leuven, Belgium (with a U.S. presence in Boston)  All Belgium companies → — Founded 2011
Healthcare Conglomerate Imaging AI Specialist Specialty-Focused AI
Acquired/Merged (formerly VC-backed)

Products

icobrain aria
icometrix (now a GE HealthCare company)
Neurology AI
icobrain aria is an AI-powered software by icometrix for automated detection, measurement, and severity assessment of Amyloid-Related Imaging Abnormalities (ARIA) on brain MRI scans, crucial for monitoring Alzheimer's patients on amyloid-targeting therapies.

See all 1 product →

About icometrix (now a GE HealthCare company)

Icometrix, now a GE HealthCare company, specializes in AI-powered software solutions for the quantitative analysis of brain MRI and CT scans. Their flagship product, icobrain, is designed to assist radiologists and neurologists in diagnosing, monitoring, and evaluating treatment responses for a wide range of neurological disorders. This includes conditions such as multiple sclerosis, Alzheimer’s disease, dementia, epilepsy, stroke, traumatic brain injury, and Parkinson’s disease. The software extracts clinically meaningful information, such as lesion and brain volume changes, and identifies patterns in brain volume loss, which are crucial for data-driven clinical decision-making.

One notable solution is icobrain aria, the first FDA-cleared AI software for detecting and grading Amyloid-Related Imaging Abnormalities (ARIA), a potential side effect of some Alzheimer’s therapies. Icometrix’s solutions are integrated into clinical workflows and aim to provide objective, reproducible insights, thereby improving efficiency in diagnosis and monitoring, and supporting personalized patient care. The company also collaborates with pharmaceutical companies on clinical trials and real-world evidence studies.

Focus Areas

AI-powered brain imaging analysis neurological disorders multiple sclerosis Alzheimer's disease dementia epilepsy stroke traumatic brain injury quantitative MRI CT scan analysis clinical decision support ARIA detection

Business Intelligence

TechnologyCloud-native (AWS), deep learning, computer vision, machine learning for image segmentation

What Physicians Need to Know

Neurological Disorders & Brain Imaging Analysis
icometrix specializes in AI-powered brain imaging analysis for a wide range of neurological disorders, including Multiple Sclerosis (MS), Alzheimer's disease, dementia, epilepsy, stroke, traumatic brain injury (TBI), Parkinson's disease, and brain tumors. Their icobrain platform extracts clinically meaningful data from MRI and CT scans to support diagnosis, monitoring, and treatment evaluation.
Amyloid-Related Imaging Abnormalities (ARIA) Detection
A key specialization is the detection, measurement, and grading of Amyloid-Related Imaging Abnormalities (ARIA), particularly with their icobrain aria solution. This is crucial for monitoring patients undergoing amyloid-targeting therapies for Alzheimer's disease, as ARIA can be a side effect. icobrain aria is the first FDA-cleared and market-approved computer-aided detection and diagnosis solution for ARIA.
Quantitative MRI & CT Scan Analysis
icometrix provides quantitative analysis of MRI and CT scans, moving from subjective assessment to a data-driven approach. Their solutions accurately visualize and quantify lesion and brain volume changes over time, aiding in differential diagnosis and monitoring atrophy.
Clinical Decision Support
The AI-driven insights from icobrain solutions assist radiologists and neurologists in making timely diagnoses and life-changing therapeutic decisions, supporting clinical decision-making efficiently and objectively.
Longitudinal Monitoring
Their technology is crucial for longitudinal brain MRI monitoring, enabling the tracking of subtle changes over time, which is vital for timely diagnoses and treatment adjustments in conditions like MS and Alzheimer's.
Technology Stack
icometrix leverages deep learning-based image segmentation, volumetric MRI analysis, and longitudinal image comparison and change detection. Their cloud-enabled analytics platform, powered by Amazon Web Services (AWS), ingests DICOM data, runs validated AI models, and delivers structured clinical reports back to hospital systems.
Physician Tip

For physicians, icometrix's AI-powered solutions, now part of GE HealthCare, offer objective, quantitative insights from brain MRI and CT scans, reducing the subjectivity and time associated with manual image interpretation. This leads to increased diagnostic accuracy, improved inter-reader agreement, and enhanced radiological reading performance, especially for subtle abnormalities and longitudinal changes. The ability to detect and quantify ARIA with icobrain aria provides critical safety monitoring for patients on amyloid-targeting Alzheimer's therapies, increasing physician confidence in prescribing these new treatments. The integration with existing hospital systems (PACS/RIS/EMR) streamlines workflows, allowing for more efficient and data-driven clinical decision-making and personalized patient care.

icometrix's icobrain platform is designed for seamless integration with hospital systems, including PACS, RIS, and EMR, facilitating automated data flows and reporting. As a GE HealthCare company, there is an anticipated integration of the icometrix icobrain platform with GE HealthCare's MRI systems for a seamless workflow, complementing GE HealthCare's existing AI-assisted scanning expertise. Beyond GE HealthCare, icometrix software also integrates with platforms from other companies such as Siemens Healthineers, Nuance, Philips Healthcare, and Guerbet. The solutions are cloud-hosted, utilizing AWS for scalable and cost-effective processing of large imaging datasets.

Products by icometrix (now a GE HealthCare company)

1 product in the directory

icobrain aria
icometrix (now a GE HealthCare company)
Neurology AI
icobrain aria is an AI-powered software by icometrix for automated detection, measurement, and severity assessment of Amyloid-Related Imaging Abnormalities (ARIA) on brain MRI scans, crucial for monitoring Alzheimer's patients on amyloid-targeting therapies.

What the Web Says

Icometrix, now a GE HealthCare company, specializes in AI-powered brain MRI analysis for neurological disorders like multiple sclerosis, dementia, and epilepsy. Their flagship product, icobrain, provides quantitative analysis of brain MRI and CT scans, offering insights for diagnosis, monitoring disease progression, and assessing treatment response. The company is recognized for its strong domain expertise in neurological AI imaging and regulatory maturity, with FDA and CE clearances for its solutions.

Overall: Mixed

Strengths

  • Exceptional technical expertise in deep learning applied to medical imaging.
  • High industry specialization with a decade-plus focus on neurological imaging.
  • Regulatory clearances (FDA and CE) provide confidence for clinical adoption.
  • Proven scalability and reliability with over 200 hospital deployments.
  • Focus on longitudinal disease monitoring provides actionable insights for neurologists.
  • Good environment, pay, perks, and management that focuses on employee well-being (based on older reviews for icometrix).

Limitations

  • Narrow vertical focus, not suitable for organizations seeking a broader medical AI partner covering other specialties.
  • Premium pricing structure, potentially a barrier for smaller clinics and regional healthcare providers.
  • HR needs improvement (based on older reviews for icometrix).
  • Potential for job insecurity and micromanagement, particularly for assembly-level positions within GE HealthCare.
  • Some GE HealthCare employees report issues with management, organizational skills, and slow processes.
  • GE HealthCare has been criticized for potentially penalizing organizations that don't purchase contracts, with high hourly rates for support.

Based on reviews from: Elion Health, SectorPunk, Indeed.com, AuntMinnie, icometrix website, AWS, GE HealthCare website, Reddit, Capterra, G2

Last updated: 2026-10-26

Videos

News, demos, and interviews about icometrix (now a GE HealthCare company).

Loading videos...

Videos load interactively. If none appear, search YouTube for icometrix (now a GE HealthCare company) →

View all on YouTube

Press & Coverage

MedTech Dive
GE HealthCare inks Icometrix buyout to acquire brain MRI software
GE HealthCare has announced its acquisition of Icometrix, a company specializing in AI-powered brain imaging analysis, for an undisclosed sum. The deal primarily focuses on Icometrix's FDA-cleared icobrain aria software, which detects side effects of Alzheimer's disease drugs. GE HealthCare plans to integrate the icobrain platform with its MRI systems and expand access to the icobrain aria module across all vendor MRI systems.
2025-09
Diagnostics World News
GE HealthCare Acquires icometrix, Beckman Coulter Launches First Fully Automated BD-Tau Immunoassay Test, More - Diagnostics World News
GE HealthCare has entered an agreement to acquire icometrix, aiming to enhance its AI-powered brain imaging analysis for neurological disorders like Alzheimer's disease. This acquisition aligns with GE HealthCare's precision care strategy, intending to strengthen clinical decision support and integrate the icobrain platform with its MRI systems.
2025-09
GE HealthCare
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
GE HealthCare announced its intent to acquire icometrix, an AI-powered brain imaging analysis company, to bolster its neurology portfolio. The acquisition will integrate icometrix's icobrain platform, including the FDA-cleared icobrain aria for detecting side effects of Alzheimer's therapies, with GE HealthCare's MRI systems.
2025-09
GE HealthCare
GE HealthCare to integrate icobrain platform with MR systems
Following its acquisition of icometrix, GE HealthCare plans to integrate the icometrix icobrain platform with its MR systems to create a seamless workflow for neurological disease assessment. The icobrain aria solution, which is FDA-cleared for detecting and quantifying side effects of amyloid-targeting therapies, is a key part of this integration.
unknown
MedPath Trial
GE HealthCare Acquires Icometrix to Strengthen Brain MRI Analysis Capabilities for Alzheimer's Drug Monitoring - MedPath Trial
GE HealthCare's acquisition of Icometrix aims to strengthen its brain MRI analysis capabilities, particularly for monitoring side effects of new Alzheimer's disease treatments. The deal highlights the growing need for specialized imaging software in this therapeutic area.
2025-09
Radiology Business
GE HealthCare to acquire Alzheimer's imaging AI firm Icometrix - Radiology Business
GE HealthCare is set to acquire Icometrix, an AI imaging firm known for its software that automates brain assessments crucial for Alzheimer's disease therapies. Icometrix has raised over $24 million in funding and its technologies are used in over 300 hospitals worldwide.
2025-09
Fierce Biotech
GE HealthCare to acquire brain MRI software developer icometrix - Fierce Biotech
GE HealthCare is acquiring icometrix to expand its brain scan portfolio, including the icobrain aria platform for detecting and quantifying side effects of Alzheimer's disease therapies. This move comes as new anti-amyloid therapies necessitate more frequent MRI scans for patient monitoring.
2025-09
MassDevice
GE HealthCare to acquire AI-powered brain imaging company Icometrix - MassDevice
GE HealthCare announced an agreement to acquire Icometrix, an AI-powered imaging analysis company focusing on neurological disorders like Alzheimer's. The acquisition aims to strengthen GE HealthCare's clinical decision support applications and integrate Icometrix's icobrain platform with its MRI systems.
2025-09

Frequently Asked Questions

icometrix, now a GE HealthCare company, offers AI-powered brain imaging analysis through its icobrain platform, which provides solutions for various neurological disorders including multiple sclerosis, dementia, Alzheimer's disease, epilepsy, stroke, traumatic brain injury, Parkinson's disease, and brain tumors. The icobrain platform extracts key data from brain MRI and CT scans to assist clinicians with diagnosis, monitoring disease progression, and personalized treatment planning.
For Multiple Sclerosis, icometrix's icobrain ms software accurately visualizes and quantifies lesion and brain volume changes over time, aiding in tracking disease progression and evaluating treatment effectiveness. For Alzheimer's disease and dementia, icobrain dm supports differential diagnosis and monitoring of atrophy, while icobrain aria is specifically designed to detect, measure, and grade Amyloid-Related Imaging Abnormalities (ARIA) which are side effects of amyloid-targeting therapies.
ARIA (Amyloid-Related Imaging Abnormalities) are known side effects, such as brain swelling (ARIA-E) and microhemorrhages (ARIA-H), associated with amyloid-targeting therapies for Alzheimer's disease. icometrix addresses these concerns with its icobrain aria solution, the first FDA-cleared AI computer-aided detection and diagnosis solution that identifies both forms of ARIA from MR scans and performs longitudinal analysis of their occurrence over time, providing radiologists with tools for monitoring patients.
icometrix's icobrain solutions are FDA-cleared and CE-marked, indicating compliance with regulatory standards for medical devices in the United States and Europe. The company itself is ISO13485, MDSAP, and ISO27001 certified, demonstrating adherence to quality management systems, regulatory requirements for medical devices, and information security management.
GE HealthCare plans to integrate the icometrix icobrain platform with its MRI systems to create a seamless workflow for analysis and reporting in neurological disease assessment. Additionally, icometrix's software has previously integrated with platforms from other companies like Philips Healthcare, Siemens Healthineers, and Nuance, demonstrating its ability to work within diverse medical imaging ecosystems.
icometrix offers support for its medical imaging solutions and AI technologies, and healthcare providers can contact them via email or phone for product inquiries, technical support, or to learn more about their software. The company also engages in partnerships, such as the collaboration with the Multiple Sclerosis Association of America (MSAA) to expand MRI access and provide AI-powered analysis for MS patients. Furthermore, icometrix collaborates with pharmaceutical companies for drug development and clinical trials.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.